Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Adelman

Pulmonary Disease Boca Raton, FL Medical Doctor

NPI 1982785689 CMS profile 316650

9980 Central Park Blvd, #322, Boca Raton, FL 33428

Open in the dashboard

General payments

$6,096

239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Adelman of Boca Raton, FL is reported in the CMS Open Payments database as having received $6,096 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,599 63
2024 General $1,270 50
2023 General $1,279 50
2022 General $540 19
2021 General $613 13
2020 General $561 30
2019 General $234 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Adelman
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Mark Adelman were reported at $1,599. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Mark Adelman Pulmonary Disease median Middle half National median
2019 $234 $377 $109–$1,340 $163
2020 $561 $230 $56–$907 $114
2021 $613 $269 $68–$1,072 $132
2022 $540 $390 $100–$1,457 $149
2023 $1,279 $419 $114–$1,659 $160
2024 $1,270 $476 $123–$1,818 $164
2025 $1,599 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,582 65 payments
  2. AstraZeneca Pharmaceuticals LP $1,364 41 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $562 24 payments
  4. W. L. Gore & Associates, Inc. $374 2 payments
  5. Genzyme Corporation $365 10 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $230 9 payments
  7. Regeneron Healthcare Solutions, Inc. $224 10 payments
  8. Insmed, Inc. $192 15 payments
  9. Baxter Healthcare $186 8 payments
  10. Amgen Inc. $168 9 payments
  11. Other $849 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,003 235 payments
  2. Education $93 4 payments
Products named General payments · program years 2019–2025
  1. FASENRA $686 19 payments
  2. OFEV $671 31 payments
  3. TRELEGY ELLIPTA $570 33 payments
  4. NUCALA $555 19 payments
  5. DUPIXENT $489 11 payments
  6. BREZTRI $448 10 payments
  7. GORE EXCLUDER AAA Endoprosthesis $374 2 payments
  8. GLASSIA $230 9 payments
  9. AIRSUPRA $229 4 payments
  10. TEZSPIRE $168 9 payments
  11. Other $2,488 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,512

Median for Pulmonary Disease: 936

Drug cost

$847,610

Median for Pulmonary Disease: $487,987

Branded share of claims

42.9%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 283 $313,333
Ofev Nintedanib Esylate Brand 13 $177,678
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 118 $136,672
Breo Ellipta Fluticasone/Vilanterol Brand 152 $105,513
Symbicort Budesonide/Formoterol Fumarate Brand 56 $18,665
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 20 $15,673
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 13 $15,376
Xarelto Rivaroxaban Brand 13 $13,843
Albuterol Sulfate Hfa Albuterol Sulfate Brand 246 $9,601
Wixela Inhub Fluticasone Propion/Salmeterol Brand 30 $6,816

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$299,750

Of which drugs: $246

Medicare patients

1,070

Average age 78

Services billed

4,459

617 women, 453 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 57%
COPD 54%
Diabetes 34%
Depression 33%
Chronic kidney disease 32%
Heart failure 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 20 20 $91
Injection, methylprednisolone acetate, 1 mg J1010 Office 35 739 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $195
$195 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $156
$156 283 —
DUPIXENT
  • GENZYME CORPORATION $82
  • Regeneron Healthcare Solutions, Inc. $67
$149 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $118
$118 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record